Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zane Kaplan

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Internal Medicine Journal|November 27, 2022
Low mortality in vaccinated immunocompromised haematology patients infected with SARS-CoV-2Briony Shaw, Jake Shortt, Michael Low, et al.
Transfusion|October 31, 2019
The cost of blood: a study of the total cost of red blood cell transfusion in patients with β-thalassemia using time-driven activity-based costingZoe K McQuilten, Alisa M Higgins, Kelly Burns, et al.
Science Translational Medicine|September 29, 2017
Neutrophil macroaggregates promote widespread pulmonary thrombosis after gut ischemiaYuping Yuan, Imala Alwis, Mike C L Wu, et al.
Lab on a Chip|June 30, 2017
Application of a strain rate gradient microfluidic device to von Willebrand's disease screeningRose J Brazilek, Francisco J Tovar-Lopez, Angus K T Wong, et al.
Internal Medicine Journal|December 8, 2023
Sickle cell disease in Australia: a snapshot from the Australian Haemoglobinopathy RegistryAnna Nelson, P Joy Ho, Helen Haysom, et al.
Internal Medicine Journal|May 6, 2025
Economic burden of sickle cell disease in AustraliaSteve Nwokeocha, Helen E Haysom, Cameron Wellard, et al.
Blood Advances|February 22, 2024
Long-term treatment with rilzabrutinib in patients with immune thrombocytopeniaDavid J Kuter, Jiri Mayer, Merlin Efraim, et al.
Internal Medicine Journal|March 7, 2025
Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approachAditya Tedjaseputra, Amanda Tey, Anastasios Nalpantidis, et al.
The New England Journal of Medicine|April 13, 2022
Rilzabrutinib, an Oral BTK Inhibitor, in Immune ThrombocytopeniaDavid J Kuter, Merlin Efraim, Jiri Mayer, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Internal Medicine Journal|November 27, 2022
Low mortality in vaccinated immunocompromised haematology patients infected with SARS-CoV-2Briony Shaw, Jake Shortt, Michael Low, et al.
Transfusion|October 31, 2019
The cost of blood: a study of the total cost of red blood cell transfusion in patients with β-thalassemia using time-driven activity-based costingZoe K McQuilten, Alisa M Higgins, Kelly Burns, et al.
Science Translational Medicine|September 29, 2017
Neutrophil macroaggregates promote widespread pulmonary thrombosis after gut ischemiaYuping Yuan, Imala Alwis, Mike C L Wu, et al.
Lab on a Chip|June 30, 2017
Application of a strain rate gradient microfluidic device to von Willebrand's disease screeningRose J Brazilek, Francisco J Tovar-Lopez, Angus K T Wong, et al.
Internal Medicine Journal|December 8, 2023
Sickle cell disease in Australia: a snapshot from the Australian Haemoglobinopathy RegistryAnna Nelson, P Joy Ho, Helen Haysom, et al.
Internal Medicine Journal|May 6, 2025
Economic burden of sickle cell disease in AustraliaSteve Nwokeocha, Helen E Haysom, Cameron Wellard, et al.
Blood Advances|February 22, 2024
Long-term treatment with rilzabrutinib in patients with immune thrombocytopeniaDavid J Kuter, Jiri Mayer, Merlin Efraim, et al.
Internal Medicine Journal|March 7, 2025
Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approachAditya Tedjaseputra, Amanda Tey, Anastasios Nalpantidis, et al.
The New England Journal of Medicine|April 13, 2022
Rilzabrutinib, an Oral BTK Inhibitor, in Immune ThrombocytopeniaDavid J Kuter, Merlin Efraim, Jiri Mayer, et al.
Pageof 2